Montelukast API Companies

Top Industry Leaders in the Montelukast API Market

Latest Montelukast Active Pharmaceutical Ingredient Companies Update

May 2023: Montelukast active pharmaceutical ingredient market leader Sandoz has announced a €25 million investment in its Holzkirchen, Germany, manufacturing facility to increase its biosimilar research capacities. By the fourth quarter of 2023, the business plans to have expanded its Biopharma Technical Development (BioTD) capabilities and converted the lab building into a cutting-edge biotech facility. The funding will be used to consolidate state-of-the-art labs and analytical resources into one convenient location. The funding "further solidifies Bavaria's standing as a prominent biotechnology powerhouse. Up to 45 full-time employees are likely to join the site as a result of capacity development and engagement with universities in Munich and research organizations, as stated by Sandoz.

July 2023: An estimated USD 90 million was disclosed by Sandoz, a world leader in generic and biosimilar pharmaceuticals including the Montelukast API. This investment would position Sandoz's Ljubljana facility as a significant hub for the company's research and development of biosimilar products. About two hundred new permanent employment will be created as a result of the relocation, and the company's capacity for developing biosimilars from start to finish will be bolstered by the move. It also expands upon Sandoz's proven complete capabilities in Ljubljana for developing technologically challenging generic medications, particularly small molecule products.

May 2023: Sandoz, Novartis's generics subsidiary and a leader in off-patent generic and biosimilar drugs like Montelukast API, agreed to a multi-year strategic partnership with Just -Evotec Biologics, the Seattle, Washington, US subsidiary of Germany's Evotec, in May 2023. The deal includes the potential for the development and production of more biosimilars. It's the latest development in Sandoz's efforts to become an independent provider of off-patent pharmaceuticals.

List of Montelukast Active Pharmaceutical Ingredient Key companies in the market